6.1.2.2. SGLT2 Inhibitors
Please see the NHSGGC Diabetes Guidelines for further information.
Restrictions:
Restricted to use in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as add-on therapy with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control in the following situations:
- monotherapy where metformin is contraindicated or not tolerated
- dual therapy in combination with metformin when a sulphonylurea is inappropriate
- triple therapy in combination with metformin plus standard of care
- as an add-on to insulin therapy in combination with insulin plus standard of care.
Restrictions:
Restricted to the treatment of type 2 diabetes only in adult patients for whom a combination of canagliflozin and metformin is appropriate and who have demonstrated compliance issues with the separate constituents.
Restrictions:
Type 2 diabetes mellitus:
Restricted to the treatment of type 2 diabetes in adult patients as:
- Monotherapy in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed AND a sulphonylurea or pioglitazone is not appropriate
- Dual therapy in combination with metformin, when metformin alone with diet and exercise does not provide adequate glycaemic control and a sulphonylurea is inappropriate
- Triple therapy in combination with metformin and sulphonylurea, as an alternative to DPP-4 inhibitor
- In combination with insulin, when insulin with diet and exercise, does not provide adequate glycaemic control
Prescribing Notes:
Please click hyperlinks for formulary information on use in chronic heart failure and chronic kidney disease.
Restrictions:
Restricted to use only in adult patients for whom a combination of dapagliflozin and metformin is appropriate and who have demonstrated compliance issues with the separate constituents.
Restrictions:
It is restricted to initiation in adult patients:
- As monotherapy in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control and only if a DPP-4 inhibitor would otherwise be prescribed and a sulphonylurea or pioglitazone is not appropriate
- As dual therapy in combination with metformin, when a sulphonylurea is inappropriate
- As triple therapy in combination with metformin plus standard of care or as add-on to insulin therapy in combination with insulin plus standard of care.
Restrictions:
Restricted to the treatment of type 2 diabetes mellitus when metformin and/or a sulfonylurea and one, or both, of the two components do not provide adequate glycaemic control.
Prescribing Notes:
NHSGGC Diabetes Guidelines click here
Restrictions:
Restricted to use in patients with type 2 diabetes mellitus for whom this fixed dose combination is considered appropriate or for use as dual therapy when a sulfonylurea is inappropriate. Additionally, it is restricted to patients who have demonstrated compliance issues with the separate constituents.
Restrictions:
Restricted to use as monotherapy and add-on therapy. When used as monotherapy, it is restricted to patients who would otherwise receive a dipeptidyl peptidase-4 inhibitor and in whom a sulfonylurea or pioglitazone is not appropriate.